Spots Global Cancer Trial Database for Genetics of Women With Lobular Carcinoma in Situ of the Breast

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Genetics of Women With Lobular Carcinoma in Situ of the Breast

Official Title: GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope

Study ID: NCT00536718

Conditions

Breast Cancer

Interventions

gene expression analysis

molecular diagnostic method

polymorphism analysis

protein expression analysis

medical chart review

questionnaire administration

Study Description

Brief Summary: RATIONALE: Gathering information about genetic changes in patients with lobular carcinoma in situ of the breast may help doctors learn more about the disease and find better methods of treatment. PURPOSE: This clinical trial is studying the genetics of women with lobular carcinoma in situ of the breast.

Detailed Description: OBJECTIVES: Primary * Identify inherited variation that predisposes women to develop lobular carcinoma in situ (LCIS) of the breast. * Identify the frequency of these variants and determine the effect they have on tumor risk. * Determine how worthwhile it would be to test for these variants in the clinical setting so that those at higher risk could be identified, counseled, and screened. Secondary * Analysis of genetic changes within LCIS with the aim of identifying cases of LCIS which may progress to invasive cancer. OUTLINE: Patients and control participants undergo blood collection. DNA is extracted from blood samples and used to genotype at selected polymorphisms, compare allele frequencies (used to associate alleles with disease) using a genome-wide single nucleotide polymorphism (SNP) screen. Archival tumor samples (if available) from patients are used for DNA-, RNA-, or protein-based analyses. All participants complete a questionnaire about family history, a brief medical history, and provide epidemiological data to a genetic counselor. Participants identified to be at risk for known hereditary predisposition to cancer will be referred to a clinical genetics service. Individual results of this study are not disclosed to participants. Peer Reviewed and Funded or Endorsed by Cancer Research UK. PROJECTED ACCRUAL: A total of 2,000 participants (1,000 patients and 1,000 matched controls) will be accrued for this study.